Portal de Periódicos da CAPES

2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project

2017; European Centre for Disease Prevention and Control; Volume: 22; Issue: 30 Linguagem: Inglês

10.2807/1560-7917.es.2017.22.30.30580

1560-7917

Marc Rondy, Amparo Larrauri, Itziar Casado, Valeria Alfonsi, Daniela Pițigoi, Odile Launay, Ritva Syrjänen, Giedrė Gefenaitė, Ausenda Machado, Vesna Višekruna Vučina, J Horváth, Iwona Paradowska‐Stankiewicz, Sierk Marbus, Alin Gherasim, Jorge Díaz-González, Caterina Rizzo, Bruno Lina, Florence Galtier, Niina Ikonen, Auksė Mickienė, Verónica Gómez, Sanja Filipović, Annamária Ferenczi, Monika R Korcinska, Rianne van Gageldonk-Lafeber, Marta Valenciano,

Pneumonia and Respiratory Infections

We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.